ELTP (Elite Pharmaceuticals) DeferredTaxAndRevenue: $0.0 Mil (As of Mar. 2026)


ELTP Elite Pharmaceuticals Inc ELTP
60 GF Score
Price $0.34
GF Value $0.56
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Elite Pharmaceuticals DeferredTaxAndRevenue?

Elite Pharmaceuticals ELTP -5.20% 60 DeferredTaxAndRevenue is $0.0 Mil as of Mar. 2026. GuruFocus rates ELTP with a GF Score™ of 60/100 and a GF Value™ of $0.56 (Possible Value Trap). The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Elite Pharmaceuticals's current deferred tax and revenue for the quarter that ended in Mar. 2026 was $0.0 Mil.

Elite Pharmaceuticals DeferredTaxAndRevenue Related Terms

Elite Pharmaceuticals DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Elite Pharmaceuticals's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elite Pharmaceuticals DeferredTaxAndRevenue Chart

Elite Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.00

Elite Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00
ELTP
60GF Score
Elite Pharmaceuticals Inc ELTP
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.0 Mil mean?
Elite Pharmaceuticals (ELTP) has a DeferredTaxAndRevenue of $0.0 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Elite Pharmaceuticals.
Is Elite Pharmaceuticals' DeferredTaxAndRevenue too high?
Elite Pharmaceuticals' current DeferredTaxAndRevenue is $0.0 Mil. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' DeferredTaxAndRevenue compare to EBS and NIKA?
Elite Pharmaceuticals' DeferredTaxAndRevenue of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Drug Manufacturers company?
A good DeferredTaxAndRevenue depends on the Drug Manufacturers industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Elite Pharmaceuticals. Elite Pharmaceuticals's current DeferredTaxAndRevenue is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.56, compared to a current price of $0.34 — trading 39.1% below its estimated fair value. The current DeferredTaxAndRevenue is $0.0 Mil. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current DeferredTaxAndRevenue is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?

Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued. The current stock price of $0.34 is trading 39.1% below its estimated GF Value™ of $0.56. GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.

Key valuation signals for ELTP:

  • DeferredTaxAndRevenue: $0.0 Mil
  • GF Value™: $0.56 vs. price of $0.34 (39.1% below fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elite Pharmaceuticals Business Description

Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score

Get the complete analysis for ELTP

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price
$0.56
GF Value